| P50 | author | Erika Penz | Q60887581 |
| | Najib M Rahman | Q37834552 |
| P2093 | author name string | Ioannis Psallidas | |
| | Christopher A Hergott | |
| | Kristina N Watt | |
| P2860 | cites work | Catheter tract metastasis associated with indwelling pleural catheters | Q38199983 |
| | Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. | Q38471302 |
| | Malignant pleural effusion: from bench to bedside | Q38849556 |
| | A commercially available preparation of Staphylococcus aureus bio-products potently inhibits tumour growth in a murine model of mesothelioma. | Q38966046 |
| | Cost-effectiveness of indwelling pleural catheter compared with talc in malignant pleural effusion. | Q39094916 |
| | Randomized Trial of Pleural Fluid Drainage Frequency in Patients with Malignant Pleural Effusions. The ASAP Trial | Q39145660 |
| | Comparison of modified Borg scale and visual analog scale dyspnea scores in predicting re-intervention after drainage of malignant pleural effusion | Q39224116 |
| | Malignant pleural effusion in the presence of trapped lung. Five-year experience of PleurX tunnelled catheters. | Q39300471 |
| | Management of malignant pleural effusion associated with trapped lung syndrome | Q39321598 |
| | Secreted phosphoprotein-1 directly provokes vascular leakage to foster malignant pleural effusion. | Q39389185 |
| | Use of an implantable pleural catheter for trapped lung syndrome in patients with malignant pleural effusion. | Q39417909 |
| | A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions | Q39434666 |
| | Breast cancer complicated by pleural effusion: patient characteristics and results of surgical management | Q39476690 |
| | State of the art. The pleura | Q39547964 |
| | Cytologic detection of malignancy in pleural effusion: a review of 5,255 samples from 3,811 patients | Q39770500 |
| | Rapid pleurodesis for malignant pleural effusions: a pilot study | Q39829790 |
| | The malignant pleural effusion. A review of cytopathologic diagnoses of 584 specimens from 472 consecutive patients | Q39859213 |
| | A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion. | Q39931549 |
| | Isolated pleural effusion in small cell lung carcinoma: favorable prognosis. A review of the Southwest Oncology Group experience | Q40127980 |
| | ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model | Q40265788 |
| | [Thoracoscopic pleurodesis in malignant pleural effusions]. | Q40481504 |
| | Effects of intrapleural mitoxantrone and mepacrine on malignant pleural effusion--a randomised study. | Q40677186 |
| | Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion | Q40723534 |
| | A comparative trial of LC9018 plus doxorubicin and doxorubicin alone for the treatment of malignant pleural effusion secondary to lung cancer | Q40744034 |
| | Pleuroscopic Pleurodesis Combined With Tunneled Pleural Catheter for Management of Malignant Pleural Effusion: A Prospective Observational Study | Q40746806 |
| | Management of Malignant Pleural Effusion: A Cost-Utility Analysis | Q40746817 |
| | Prognostic Factors of 30-Day Mortality After Palliative Procedures in Patients with Malignant Pleural Effusion | Q41251928 |
| | Pleural diseases related to metastatic malignancies | Q41578726 |
| | Talc pleurodesis through indwelling pleural catheters for malignant pleural effusions: retrospective case series of a novel clinical pathway. | Q41632832 |
| | Metastatic carcinoma of the pleura | Q41948072 |
| | Survival time of patients with pleural metastatic carcinoma predicted by glucose and pH studies | Q42150022 |
| | Infections associated with tunnelled indwelling pleural catheters in patients undergoing chemotherapy | Q42242881 |
| | Optimal management of malignant pleural effusions (results of CALGB 30102). | Q42275284 |
| | Diagnostic value and prognostic significance of pleural C-reactive protein in lung cancer patients with malignant pleural effusions | Q43244893 |
| | Novel use of pleural ultrasound can identify malignant entrapped lung prior to effusion drainage | Q43491564 |
| | Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial | Q43686149 |
| | Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer‑mediated malignant pleural effusion | Q43910138 |
| | Diagnosis and prognostic factors in malignant pleural mesothelioma: a retrospective analysis of sixty-five patients | Q44400584 |
| | Clinical and pathological factors influencing the survival of breast cancer patients with malignant pleural effusion | Q44513237 |
| | The cytologic diagnosis of malignant neoplasms in pleural and peritoneal effusions | Q44813554 |
| | Indwelling pleural catheters reduce inpatient days over pleurodesis for malignant pleural effusion. | Q44855468 |
| | Malignant pleural effusions: meaning of pleural-fluid pH determination | Q44888257 |
| | Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study | Q46555853 |
| | Long-term indwelling pleural catheter (PleurX) for malignant pleural effusion unsuitable for talc pleurodesis | Q47440359 |
| | The impact of tunneled pleural catheters on the quality of life of patients with malignant pleural effusions | Q48354741 |
| | Thoracoscopic palliative treatment of malignant pleural effusions: results in 273 patients | Q48693537 |
| | EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases | Q49089662 |
| | Procedures Performed during Hospitalizations for Malignant Pleural Effusions: Data from the 2012 National Inpatient Sample | Q50134009 |
| | Comparing cost of indwelling pleural catheter vs talc pleurodesis for malignant pleural effusion. | Q50684480 |
| | Diagnostic and prognostic significance of survivin levels in malignant pleural effusion. | Q50887353 |
| | Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. | Q51271432 |
| | Long-term follow-up of video-assisted talc pleurodesis in malignant recurrent pleural effusions. | Q51336566 |
| | Use of lipoteichoic acid-T for pleurodesis in malignant pleural effusion: a phase I toxicity and dose-escalation study. | Q53209076 |
| | Malignant Pleural Effusion: Prognostic Factors for Survival and Response to Chemical Pleurodesis in a Series of 120 Cases | Q64130785 |
| | [Clinical research on recombinant human Ad-p53 injection combined with cisplatin in treatment of malignant pleural effusion induced by lung cancer] | Q64375065 |
| | Efficacy of Pleural Needle Biopsy and Pleural Fluid Cytopathology in the Diagnosis of Malignant Neoplasm Involving the Pleura | Q66922414 |
| | Pathogenesis of pleural effusion in carcinoma of the breast | Q67043230 |
| | Carcinomatous involvement of the pleura: an analysis of 96 patients | Q67735451 |
| | Pleural metastatic tumours and effusions. Frequency and pathogenic mechanisms in a post-mortem series | Q69740168 |
| | Observations on pleural fluid pressures as fluid is withdrawn during thoracentesis | Q71287932 |
| | Interventions for the management of malignant pleural effusions: a network meta-analysis | Q24185776 |
| | Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010 | Q28290042 |
| | Pleural fluid pH in malignant effusions. Diagnostic, prognostic, and therapeutic implications | Q28296374 |
| | Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion | Q30366235 |
| | Permanent indwelling catheters in the management of pleural effusions | Q30456298 |
| | Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial | Q30790098 |
| | A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A. | Q33434866 |
| | Management of malignant pleural effusions | Q33924596 |
| | Treatment of malignant pleural effusion: PleuRx catheter or talc pleurodesis? A cost-effectiveness analysis | Q34129663 |
| | Efficacy and safety of tunneled pleural catheters in adults with malignant pleural effusions: a systematic review | Q34505962 |
| | Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. | Q34608340 |
| | The efficacy of indwelling pleural catheter placement versus placement plus talc sclerosant in patients with malignant pleural effusions managed exclusively as outpatients (IPC-PLUS): study protocol for a randomised controlled trial. | Q35097374 |
| | Important prognostic factors for survival in patients with malignant pleural effusion | Q35232954 |
| | BTS guidelines for the management of malignant pleural effusions | Q35577474 |
| | Breast cancer and thoracic metastases: review of 119 patients | Q36126930 |
| | Serous effusions in malignant lymphomas: a review | Q36444591 |
| | Malignant pleural effusion treatment outcomes: pleurodesis via video-assisted thoracic surgery (VATS) versus tube thoracostomy | Q36562893 |
| | Thoracoscopy. A prospective study of safety and outcome | Q36689614 |
| | Management of malignant pleural effusions with indwelling pleural catheters or talc pleurodesis | Q36777607 |
| | Predictors of survival in patients who underwent video-assisted thoracic surgery talc pleurodesis for malignant pleural effusion | Q37060372 |
| | Treatment of malignant pleural effusion: a cost-effectiveness analysis | Q37199528 |
| | Malignant pleural effusion: tumor-host interactions unleashed | Q38015001 |
| | Symptom management in patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. | Q38104635 |
| | Clinical outcomes of indwelling pleural catheter-related pleural infections: an international multicenter study. | Q38119425 |
| | Pleural fluid pH as a predictor of survival for patients with malignant pleural effusions | Q73344976 |
| | Malignancy metastatic to the pleura | Q74730332 |
| | Bevacizumab is active in malignant effusion | Q79766458 |
| | Video-assisted thoracoscopic (VATS) pleurodesis for malignant effusion: an Australian teaching hospital's experience | Q81622813 |
| | Management of malignant pleural effusions | Q81803062 |
| | Prognostic factors in patients presenting with pleural effusion revealing malignancy | Q87155131 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | malignant pleural effusion | Q6743514 |
| P304 | page(s) | 229-241 | |
| P577 | publication date | 2017-06-23 | |
| P1433 | published in | Cancer Management and Research | Q5031417 |
| P1476 | title | Management of malignant pleural effusion: challenges and solutions | |
| P478 | volume | 9 | |